Amporin Pharmaceuticals AG
- Biotech or pharma, therapeutic R&D
Amporin Pharmaceuticals AG is an emerging Swiss biotech company founded in 2024 by a small team of industry-seasoned drug discovery and development professionals. We are developing a breakthrough new class of small molecule "amyloid pore"inhibitors that can uniquely fix the holes in cell membranes formed by toxic soluble misfolded protein oligomers, as the first potential acute oral disease-modifying treatments to stop and reverse the progression of over 50 deadly degenerative diseases associated with protein misfolding and aggregation, including Alzheimer's, Parkinson's, Huntington's, ALS, type II diabetes, and many rare degenerative diseases. By directly targeting the fundamental molecular mechanism that causes all these diseases, our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}